<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000 Med Rep</journal-id><journal-title-group><journal-title>F1000 Medicine Reports</journal-title></journal-title-group><issn pub-type="epub">1757-5931</issn><publisher><publisher-name>Medicine Reports Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20948870</article-id><article-id pub-id-type="pmc">2948376</article-id><article-id pub-id-type="doi">10.3410/M2-16</article-id><article-id pub-id-type="publisher-id">16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guglielmelli</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Vannucchi</surname><given-names>Alessandro M</given-names></name><xref ref-type="aff" rid="aff1"/><ext-link ext-link-type="uri" xlink:href="http://f1000medicine.com/member/5773110212162140"/><email xlink:href="mailto:amvannucchi@unifi.it">amvannucchi@unifi.it</email></contrib><aff id="aff1"><institution>Division of Hematology, Department of Critical Care, University of Florence</institution><addr-line>Viale G Morgagni 85, 50134 Firenze</addr-line><country>Italy</country></aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>2</month><year>2010</year></pub-date><pub-date pub-type="collection"><year>2010</year></pub-date><volume>2</volume><elocation-id>16</elocation-id><permissions><copyright-statement>&#x000a9; 2010 Medicine Reports Ltd</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/legalcode"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution-Non Commercial License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original
work is properly cited. You may not use this work for commercial purposes</license-p></license></permissions><abstract><p>The Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) have recently been the focus of tremendous advances in basic knowledge of disease pathophysiology following the recognition of mutations in <italic>JAK2</italic> and <italic>MPL</italic>. These discoveries also led to refinement of the criteria employed for diagnosis. The prognostic roles of the <italic>JAK2</italic> V617F mutation and of leukocytosis as independent risk factors for thrombosis, which represents the leading cause of death in patients with polycythemia vera and essential thrombocythemia, are supported by retrospective studies. A new risk stratification approach to the patient with primary myelofibrosis allows clinicians to distinguish categories of patients with significantly different expected survival. Finally, new drugs are currently being tested for MPNs, and molecular discoveries could ultimately lead to the development of a specific targeted therapy. Overall, significant advances in diagnosis, prognostication, and treatment have taken place in the last couple of years in the field of MPNs.</p></abstract></article-meta><notes><p>The electronic version of this article is the complete one and can be found at: <ext-link ext-link-type="uri" xlink:href="http://f1000.com/reports/m/2/16">http://f1000.com/reports/m/2/16</ext-link></p></notes></front><body><sec sec-type="" id="s01"><title>Introduction and context</title><p>The Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [<xref ref-type="bibr" rid="bib-001">1</xref>]. PV and ET are relatively indolent disorders that result in a modest reduction of survival, usually after the first decade from the time of diagnosis; PMF, on the other hand, has a more severe course and a median survival of about 5 years, although some patients experience survival of longer than 10 years. The course of PV and ET is marked by an excess of arterial and venous thrombosis, which represent the principal cause of morbidity and mortality; major hemorrhage, evolution to post-polycythemia vera/post-essential thrombocythemia myelofibrosis (PPV/PET-MF), and transformation to acute myeloid leukemia (AML) also contribute to reduced survival. Causes of death in patients with PMF are related to the consequences of myeloproliferation or bone marrow failure, vascular events, infections, and transformation to AML.</p><p>In 2005, a point mutation in exon 14 of the Janus kinase 2 gene (<italic>JAK2</italic> V617F) was discovered in the majority of patients with PV and in about 60% of those with ET or PMF [<xref ref-type="bibr" rid="bib-002">2</xref>-<xref ref-type="bibr" rid="bib-005">5</xref>]. Additional mutations in exon 12 of <italic>JAK2</italic> [<xref ref-type="bibr" rid="bib-006">6</xref>] and at codon 515 of the myeloproliferative leukemia virus oncogene (<italic>MPL</italic>) [<xref ref-type="bibr" rid="bib-007">7</xref>] were reported in a minority of patients with PV or in 5% and 10% of patients with ET and PMF, respectively. These mutant alleles all result in a gain of function due to constitutive activation of tyrosine kinase-dependent cellular signaling pathways, particularly the JAK-signal transducer and activator of transcription (JAK-STAT) pathway [<xref ref-type="bibr" rid="bib-008">8</xref>]. During the search for additional genetic abnormalities in MPNs with the use of high-resolution SNP (single-nucleotide polymorphism) analysis, a region of acquired UPD (uniparental disomy) was identified at chr4q24, where the <italic>TET2</italic> gene maps [<xref ref-type="bibr" rid="bib-009">9</xref>]. Abnormalities in <italic>TET2</italic> are believed to antedate the acquisition of <italic>JAK2</italic> V617F point mutation in most, but not all, cases [<xref ref-type="bibr" rid="bib-009">9</xref>,<xref ref-type="bibr" rid="bib-010">10</xref>]. The precise function of <italic>TET2</italic> is unknown, but the gene might behave as a <italic>bona fide</italic> oncosuppressor. However, it was soon shown that mutations in <italic>TET2</italic> are found in only 10-15% of MPN patients and are shared by other myeloid malignances, in particular myelodysplastic syndromes and chronic myelomonocytic leukemia [<xref ref-type="bibr" rid="bib-011">11</xref>-<xref ref-type="bibr" rid="bib-014">14</xref>].</p><p>Clustering of myeloproliferative disorders in some families has been recognized for some time. Furthermore, a recent epidemiologic study from Sweden found that the risk of developing an MPN is up to seven-fold greater in first-degree relatives of MPN patients than in the general population [<xref ref-type="bibr" rid="bib-015">15</xref>]. The genetic predisposition to MPN, particularly but not exclusively among patients harboring the V617F mutation, has been attributed to a specific haplotype, called 46/1 or GGCC, that is located at chromosome 9 and includes the <italic>JAK2</italic> gene itself [<xref ref-type="bibr" rid="bib-016">16</xref>-<xref ref-type="bibr" rid="bib-019">19</xref>].</p><p>Overall, this information has significantly advanced our understanding of the pathophysiology of MPN and, by pointing to mutated kinases as a common mechanism in these disorders, has suggested that tyrosine kinases might represent a valid target for therapy, as exemplified by the efficacy of imatinib and second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia.</p></sec><sec sec-type="" id="s02"><title>Recent advances</title><sec id="s02_01"><title>Diagnosis</title><p>One seminal advance has been the revision [<xref ref-type="bibr" rid="bib-020">20</xref>] of the criteria employed for diagnosis that was promoted by the demonstration of an almost universal association of the <italic>JAK2</italic> V617F mutation with PV and an association in about 60% of patients with ET or PMF. According to the 2008 World Health Organization (WHO) classification [<xref ref-type="bibr" rid="bib-021">21</xref>], the presence of any of these mutations constitutes a major criterion for diagnosis. However, the diagnosis of ET or PMF still requires expert evaluation of bone marrow histopathology in order to identify specific morphologic patterns associated with either disease. Another clinical setting in which diagnosis has been significantly improved is represented by the splancnic vein thromboses that have been found to be associated with the <italic>JAK2</italic> V617F mutation in up to half of cases [<xref ref-type="bibr" rid="bib-022">22</xref>], thus establishing an MPN as the commonest underlying cause [<xref ref-type="bibr" rid="bib-023">23</xref>]. Finally, a consensus statement from the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) proposed uniform criteria for diagnosing the evolution of PV or ET to PPV/PET-MF [<xref ref-type="bibr" rid="bib-024">24</xref>]. Overall, these molecular and clinical advances have made the diagnostic work-up of the commonest MPN more effective and reproducible, a key premise for clinical studies and for the design of trials of innovative drugs.</p></sec><sec id="s02_02"><title>Prognosis</title><p>The only criteria currently used for risk stratification of PV or ET patients are older age and previous history of thrombosis. However, several studies, supported by meta-analyses, have documented the association of the <italic>JAK2</italic> V617F mutation with an increased risk of arterial and venous thrombosis in patients with ET (hazard ratio 1.8- to 2.0-fold greater than that of <italic>JAK2</italic> unmutated ET patients) [<xref ref-type="bibr" rid="bib-025">25</xref>], particularly if the mutation is harbored in a homozygous status (i.e., both alleles are mutated) [<xref ref-type="bibr" rid="bib-026">26</xref>]. One study reported that patients with PV who have a high &#x02018;allele burden&#x02019; (i.e., a prevalence of mutated versus normal alleles) are at greater risk for thrombosis [<xref ref-type="bibr" rid="bib-027">27</xref>]. It is also possible that the accumulation of mutated alleles in PV or ET accompanies transformation to PPV/PET-MF [<xref ref-type="bibr" rid="bib-026">26</xref>,<xref ref-type="bibr" rid="bib-028">28</xref>]. On the contrary, PMF patients with lower <italic>JAK2</italic> V617F allele burden are at increased risk of death [<xref ref-type="bibr" rid="bib-029">29</xref>,<xref ref-type="bibr" rid="bib-030">30</xref>]. Thus, evidence that, in addition to diagnostic relevance, a <italic>JAK2</italic> V617F mutated status or a high burden of mutated allele or both have prognostic correlates is being accumulated [<xref ref-type="bibr" rid="bib-031">31</xref>]. On the other hand, <italic>TET2</italic> mutations have not been associated yet with clinical endpoints [<xref ref-type="bibr" rid="bib-032">32</xref>]. Finally, while it is accepted that the occurrence of thrombosis in PV or ET is not directly linked to raised hematocrit or platelet count, leukocytosis has recently been associated with increased risk of major vascular events and eventually could represent a major target of cytoreductive therapy [<xref ref-type="bibr" rid="bib-033">33</xref>].</p><p>Identification of PMF patients with expected shorter survival is pivotal for appropriate decision making in regard to hematopoietic stem cell transplantation, which offers the only chance of cure but is still burdened by significant mortality and morbidity. A new and highly discriminatory prognostic system has been devised by the IWG-MRT on the basis of a study of 1054 patients [<xref ref-type="bibr" rid="bib-034">34</xref>]. Variables predicting shortened survival were an age of greater than 65 years, presence of constitutional symptoms, hemoglobin level of less than 100 g/L, leukocyte count of greater than 25 &#x000d7; 10<sup>9</sup>/L, and percentage of circulating blast cells of 1% or greater. When these variables were used, four risk groups that differed significantly in median survival, ranging from 135 to 95, 48, and 27 months, were delineated [<xref ref-type="bibr" rid="bib-034">34</xref>]. These five variables maintained their impact on survival when analyzed as time-dependent covariates during the follow-up of PMF patients, whether younger or older than 65 years [<xref ref-type="bibr" rid="bib-035">35</xref>]. Therefore, prognostic assessment of patients with PMF can be performed anytime during their clinical course by using these criteria and may guide treatment decision.</p></sec><sec id="s02_03"><title>Treatment</title><p>The central role that alterations in the JAK-STAT pathway play in clinical manifestations of MPN has made targeting JAK2 an appealing therapeutic goal [<xref ref-type="bibr" rid="bib-036">36</xref>,<xref ref-type="bibr" rid="bib-037">37</xref>]. A number of drugs exhibiting differential inhibitory activity against JAK family members and eventually on other receptor kinases, such as FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor), and FLT3 (FMS-like tyrosine kinase 3), are currently in clinical development. Most experience has been in patients with myelofibrosis in phase I/II trials employing INCB018424 (a potent and selective inhibitor of JAK1 and JAK2), TG101348 (a structure-based drug designed to inhibit JAK2 with great selectivity), CEP-701 (a multikinase inhibitor), and XL019 (a selective JAK2 inhibitor whose clinical development has been halted because of neurotoxicity). With some differences, the first results available indicated substantial activity against enlarged spleen and systemic symptoms, whereas the effects on the mutational burden were more variable [<xref ref-type="bibr" rid="bib-038">38</xref>].</p><p>While the use of JAK2 inhibitors is ongoing, other important trials have been completed in the last two years. Lenalidomide, an immunomodulating agent, was reported to produce a 20-30% response rate in anemia and splenomegaly, and overall this is similar to the experience with thalidomide and prednisone; myelotoxicity was common [<xref ref-type="bibr" rid="bib-039">39</xref>]. Another study indicated that the combination of lenalidomide and prednisone might be better tolerated, responses were more durable, and a significant reduction of <italic>JAK2</italic> V617F allele burden was reported [<xref ref-type="bibr" rid="bib-040">40</xref>]. However, response rate and quality of response were impressive in myelofibrotic patients harboring the del(5)q abnormality, and lenalidomide should be considered as first-line therapy in this specific subset of patients [<xref ref-type="bibr" rid="bib-041">41</xref>]. A third thalidomide analog, pomalidomide, has been evaluated in a phase II randomized, multicenter, double-blind study. The drug was effective for treatment of anemia in up to 36% of the patients, with minimal hematological and extra-hematological toxicity. No changes in <italic>JAK2</italic> V617F allele burden were observed [<xref ref-type="bibr" rid="bib-042">42</xref>]. Similar results (33% for hepatosplenomegaly and 38% for transfusion-dependent anemia) were reported in a phase II trial with tipifarnib, a farnesyltransferase inhibitor [<xref ref-type="bibr" rid="bib-043">43</xref>].</p><p>The role of epigenetic abnormalities in the pathogenesis of MPNs represents a novel field of research [<xref ref-type="bibr" rid="bib-044">44</xref>]. In this regard, a recent paper reported that JAK2 possesses a nuclear activity and regulates the phosphorylation of histone H3 [<xref ref-type="bibr" rid="bib-045">45</xref>], thereby affecting the expression of target genes, including putative oncogenes such as <italic>lmo2</italic>. Furthermore, TET1, another member of the TET family, has been shown to catalyze the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, possibly intervening in the regulation of transcriptional activity [<xref ref-type="bibr" rid="bib-046">46</xref>]. These observations may have therapeutic relevance. However, two similar but independent trials failed to observe any favorable effect of 5-azacytidine in myelofibrosis [<xref ref-type="bibr" rid="bib-047">47</xref>,<xref ref-type="bibr" rid="bib-048">48</xref>]. On the contrary, ITF2387, a histone deacethylase inhibitor, was reported to have significant activity in the control of hematological abnormalities and systemic symptoms in patients with PV or ET [<xref ref-type="bibr" rid="bib-049">49</xref>].</p><p>Interferon (IFN) has been used sporadically in PV and ET for some time. In France, a phase II study of pegylated IFN-&#x003b1;-2a in PV included 40 patients. Eighty-nine percent of the patients presented a mean decrease of the V617 allele of 44%, with complete disappearance of the V617F allele in one patient. The results would confirm the hypothesis that IFN-&#x003b1; preferentially targets the malignant clone in PV [<xref ref-type="bibr" rid="bib-050">50</xref>].</p><p>The availability of novel drugs calls for the need to have standardized criteria for assessing response to therapy. While response criteria in patients with PMF were published several years ago [<xref ref-type="bibr" rid="bib-051">51</xref>,<xref ref-type="bibr" rid="bib-052">52</xref>], criteria of response to treatment in PV and ET patients have been published only recently following a European consensus conference [<xref ref-type="bibr" rid="bib-053">53</xref>].</p></sec></sec><sec sec-type="" id="s03"><title>Implications for clinical practice</title><p>Testing of the <italic>JAK2</italic> V617F and, more selectively, <italic>MPL</italic> W515L/K/A or <italic>JAK2</italic> exon 12 mutational statuses has made the diagnosis of MPN more precise than ever before. Therefore, genotyping for those mutations is mandatory in the work-up of a patient suspected of having an MPN. Nowadays, diagnoses are expected to strictly fulfill the 2008 WHO criteria. Also, the IWG-MRT criteria for the diagnosis of PPV/PET-MF should be routinely adopted in clinical practice. Genotype-phenotype associations have been identified; however, quantitative methods for measuring <italic>JAK2</italic> V617F allele burden are specialized tools that are still best used within clinical trials. After all, the decision to treat ET or PV patients based on the presence of the mutation, a high mutated allele burden, or leukocytosis as surrogate markers of increased thrombotic risk deserves prospective validation and cannot be routinely recommended outside clinical trials.</p><p>It is now time to start assuming that the clinical course of MPNs may be improved by therapy and the disease possibly cured. Molecular discoveries have made the development of JAK2 tyrosine kinase inhibitors an attractive therapeutic goal, and molecules that inhibit JAK2 kinase are being evaluated with measurable results in the clinical setting. Actually, the rapid and marked improvement in splenomegaly and quality of life observed in myelofibrotic patients treated with INCB018424 or TG101348 has never been seen before with any drug and <italic>per se</italic> justify enthusiasm. Novel immunomodulatory agents may be better tolerated and more effective than thalidomide in the setting of myelofibrosis. Drugs acting on epigenetic gene regulation, either alone or eventually in combination, hold some promise. Finally, while it is noteworthy that IFN proved able to induce clonal remission in patients with PV, larger studies are needed to define the proportion of patients achieving such a goal as well as the long-term treatment tolerability of pegylated formulations. However, whether aiming at molecular remission is a valuable clinical endpoint for the long-term management of PV or ET, as it might be for myelofibrosis, still requires demonstration.</p></sec></body><back><notes><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></notes><ref-list><title>References</title><ref id="bib-001"><label>1</label><element-citation publication-type="journal"><person-group><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>Advances in understanding and management of myeloproliferative neoplasms</article-title><source>CA Cancer J Clin</source><year>2009</year><volume>59</volume><fpage>171</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">19369682</pub-id><pub-id pub-id-type="doi">10.3322/caac.20009</pub-id></element-citation></ref><ref id="bib-002"><label>2</label><element-citation publication-type="journal"><person-group><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Huntly</surname><given-names>BJ</given-names></name><name><surname>Boggon</surname><given-names>TJ</given-names></name><name><surname>Wlodarska</surname><given-names>I</given-names></name><name><surname>Clark</surname><given-names>JJ</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Adelsperger</surname><given-names>J</given-names></name><name><surname>Koo</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Mercher</surname><given-names>T</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>A</given-names></name><name><surname>Frohling</surname><given-names>S</given-names></name><name><surname>Dohner</surname><given-names>K</given-names></name><name><surname>Marynen</surname><given-names>P</given-names></name><name><surname>Vandenberghe</surname><given-names>P</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Griffin</surname><given-names>JD</given-names></name><name><surname>Eck</surname><given-names>MJ</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name></person-group><article-title>Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</article-title><source>Cancer Cell</source><year>2005</year><volume>7</volume><fpage>387</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">15837627</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2005.03.023</pub-id></element-citation></ref><ref id="bib-003"><label>3</label><element-citation publication-type="journal"><person-group><name><surname>James</surname><given-names>C</given-names></name><name><surname>Ugo</surname><given-names>V</given-names></name><name><surname>Le Couedic</surname><given-names>JP</given-names></name><name><surname>Staerk</surname><given-names>J</given-names></name><name><surname>Delhommeau</surname><given-names>F</given-names></name><name><surname>Lacout</surname><given-names>C</given-names></name><name><surname>Garcon</surname><given-names>L</given-names></name><name><surname>Raslova</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name><name><surname>Bennaceur-Griscelli</surname><given-names>A</given-names></name><name><surname>Villeval</surname><given-names>JL</given-names></name><name><surname>Constantinescu</surname><given-names>SN</given-names></name><name><surname>Casadevall</surname><given-names>N</given-names></name><name><surname>Vainchenker</surname><given-names>W</given-names></name></person-group><article-title>A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>1144</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15793561</pub-id><pub-id pub-id-type="doi">10.1038/nature03546</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000biology.com/article/id/1026013">f1000 Factor 6.0 <italic>Must Read</italic></ext-link></p><p>Evaluated by Hans Clevers 25 May 2005</p></note></ref><ref id="bib-004"><label>4</label><element-citation publication-type="journal"><person-group><name><surname>Kralovics</surname><given-names>R</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Buser</surname><given-names>AS</given-names></name><name><surname>Teo</surname><given-names>SS</given-names></name><name><surname>Tiedt</surname><given-names>R</given-names></name><name><surname>Passweg</surname><given-names>JR</given-names></name><name><surname>Tichelli</surname><given-names>A</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Skoda</surname><given-names>RC</given-names></name></person-group><article-title>A gain-of-function mutation of JAK2 in myeloproliferative disorders</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1779</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15858187</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa051113</pub-id></element-citation></ref><ref id="bib-005"><label>5</label><element-citation publication-type="journal"><person-group><name><surname>Baxter</surname><given-names>EJ</given-names></name><name><surname>Scott</surname><given-names>LM</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>East</surname><given-names>C</given-names></name><name><surname>Fourouclas</surname><given-names>N</given-names></name><name><surname>Swanton</surname><given-names>S</given-names></name><name><surname>Vassiliou</surname><given-names>GS</given-names></name><name><surname>Bench</surname><given-names>AJ</given-names></name><name><surname>Boyd</surname><given-names>EM</given-names></name><name><surname>Curtin</surname><given-names>N</given-names></name><name><surname>Scott</surname><given-names>MA</given-names></name><name><surname>Erber</surname><given-names>WN</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name></person-group><article-title>Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1054</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">15781101</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)71142-9</pub-id></element-citation></ref><ref id="bib-006"><label>6</label><element-citation publication-type="journal"><person-group><name><surname>Scott</surname><given-names>LM</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Scott</surname><given-names>MA</given-names></name><name><surname>Beer</surname><given-names>PA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Erber</surname><given-names>WN</given-names></name><name><surname>McMullin</surname><given-names>MF</given-names></name><name><surname>Harrison</surname><given-names>CN</given-names></name><name><surname>Warren</surname><given-names>AJ</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name></person-group><article-title>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>459</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">17267906</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa065202</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1068772">f1000 Factor 3.0 <italic>Recommended</italic></ext-link></p><p>Evaluated by Srdan Verstovsek 23 Mar 2007</p></note></ref><ref id="bib-007"><label>7</label><element-citation publication-type="journal"><person-group><name><surname>Pikman</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Mercher</surname><given-names>T</given-names></name><name><surname>McDowell</surname><given-names>E</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gozo</surname><given-names>M</given-names></name><name><surname>Cuker</surname><given-names>A</given-names></name><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Galinsky</surname><given-names>I</given-names></name><name><surname>DeAngelo</surname><given-names>DJ</given-names></name><name><surname>Clark</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><article-title>MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia</article-title><source>PLoS Med</source><year>2006</year><volume>3</volume><fpage>e270</fpage><pub-id pub-id-type="pmid">16834459</pub-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0030270</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1053679">f1000 Factor 3.0 <italic>Recommended</italic></ext-link></p><p>Evaluated by Srdan Verstovsek 07 Dec 2006</p></note></ref><ref id="bib-008"><label>8</label><element-citation publication-type="journal"><person-group><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name></person-group><article-title>Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>673</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">17721432</pub-id><pub-id pub-id-type="doi">10.1038/nrc2210</pub-id></element-citation></ref><ref id="bib-009"><label>9</label><element-citation publication-type="journal"><person-group><name><surname>Delhommeau</surname><given-names>F</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Della Valle</surname><given-names>V</given-names></name><name><surname>James</surname><given-names>C</given-names></name><name><surname>Trannoy</surname><given-names>S</given-names></name><name><surname>Masse</surname><given-names>A</given-names></name><name><surname>Kosmider</surname><given-names>O</given-names></name><name><surname>Le Couedic</surname><given-names>JP</given-names></name><name><surname>Robert</surname><given-names>F</given-names></name><name><surname>Alberdi</surname><given-names>A</given-names></name><name><surname>Lecluse</surname><given-names>Y</given-names></name><name><surname>Plo</surname><given-names>I</given-names></name><name><surname>Dreyfus</surname><given-names>FJ</given-names></name><name><surname>Marzac</surname><given-names>C</given-names></name><name><surname>Casadevall</surname><given-names>N</given-names></name><name><surname>Lacombe</surname><given-names>C</given-names></name><name><surname>Romana</surname><given-names>SP</given-names></name><name><surname>Dessen</surname><given-names>P</given-names></name><name><surname>Soulier</surname><given-names>J</given-names></name><name><surname>Viguie</surname><given-names>F</given-names></name><name><surname>Fontenay</surname><given-names>M</given-names></name><name><surname>Vainchenker</surname><given-names>W</given-names></name><name><surname>Bernard</surname><given-names>OA</given-names></name></person-group><article-title>Mutation in TET2 in myeloid cancers</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>2289</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">19474426</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa0810069</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1163492">f1000 Factor 3.0 <italic>Recommended</italic></ext-link></p><p>Evaluated by Richard Larson 25 Aug 2009</p></note></ref><ref id="bib-010"><label>10</label><element-citation publication-type="journal"><person-group><name><surname>Saint-Martin</surname><given-names>C</given-names></name><name><surname>Leroy</surname><given-names>G</given-names></name><name><surname>Delhommeau</surname><given-names>F</given-names></name><name><surname>Panelatti</surname><given-names>G</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>C</given-names></name><name><surname>Plo</surname><given-names>I</given-names></name><name><surname>Bordessoule</surname><given-names>D</given-names></name><name><surname>Chomienne</surname><given-names>C</given-names></name><name><surname>Delannoy</surname><given-names>A</given-names></name><name><surname>Devidas</surname><given-names>A</given-names></name><name><surname>Gardembas-Pain</surname><given-names>M</given-names></name><name><surname>Isnard</surname><given-names>F</given-names></name><name><surname>Plumelle</surname><given-names>Y</given-names></name><name><surname>Bernard</surname><given-names>O</given-names></name><name><surname>Vainchenker</surname><given-names>W</given-names></name><name><surname>Najman</surname><given-names>A</given-names></name><name><surname>Bellanne-Chantelot</surname><given-names>C</given-names></name></person-group><article-title>Analysis of the ten-eleven translocation (TET)2 gene in familial myeloproliferative neoplasms</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>1628</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">19564637</pub-id><pub-id pub-id-type="doi">10.1182/blood-2009-01-197525</pub-id></element-citation></ref><ref id="bib-011"><label>11</label><element-citation publication-type="journal"><person-group><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Mullally</surname><given-names>A</given-names></name><name><surname>Hedvat</surname><given-names>C</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Malinge</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Kilpivaara</surname><given-names>O</given-names></name><name><surname>Bhat</surname><given-names>R</given-names></name><name><surname>Huberman</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Dolgalev</surname><given-names>I</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Le Beau</surname><given-names>MM</given-names></name><name><surname>Beran</surname><given-names>M</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Crispino</surname><given-names>JD</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><article-title>Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>144</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19420352</pub-id><pub-id pub-id-type="doi">10.1182/blood-2009-03-210039</pub-id></element-citation></ref><ref id="bib-012"><label>12</label><element-citation publication-type="journal"><person-group><name><surname>Jankowska</surname><given-names>AM</given-names></name><name><surname>Szpurka</surname><given-names>H</given-names></name><name><surname>Tiu</surname><given-names>RV</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><name><surname>Afable</surname><given-names>M</given-names></name><name><surname>Huh</surname><given-names>J</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>CL</given-names></name><name><surname>Ganetzky</surname><given-names>R</given-names></name><name><surname>McDevitt</surname><given-names>MA</given-names></name><name><surname>Maciejewski</surname><given-names>JP</given-names></name></person-group><article-title>Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>6403</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">19372255</pub-id><pub-id pub-id-type="doi">10.1182/blood-2009-02-205690</pub-id></element-citation></ref><ref id="bib-013"><label>13</label><element-citation publication-type="journal"><person-group><name><surname>Langemeijer</surname><given-names>SM</given-names></name><name><surname>Kuiper</surname><given-names>RP</given-names></name><name><surname>Berends</surname><given-names>M</given-names></name><name><surname>Knops</surname><given-names>R</given-names></name><name><surname>Aslanyan</surname><given-names>MG</given-names></name><name><surname>Massop</surname><given-names>M</given-names></name><name><surname>Stevens-Linders</surname><given-names>E</given-names></name><name><surname>van Hoogen</surname><given-names>P</given-names></name><name><surname>van Kessel</surname><given-names>AG</given-names></name><name><surname>Raymakers</surname><given-names>RA</given-names></name><name><surname>Kamping</surname><given-names>EJ</given-names></name><name><surname>Verhoef</surname><given-names>GE</given-names></name><name><surname>Verburgh</surname><given-names>E</given-names></name><name><surname>Hagemeijer</surname><given-names>A</given-names></name><name><surname>Vandenberghe</surname><given-names>P</given-names></name><name><surname>de Witte</surname><given-names>T</given-names></name><name><surname>van der Reijden</surname><given-names>BA</given-names></name><name><surname>Jansen</surname><given-names>JH</given-names></name></person-group><article-title>Acquired mutations in TET2 are common in myelodysplastic syndromes</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>838</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">19483684</pub-id><pub-id pub-id-type="doi">10.1038/ng.391</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1163056">f1000 Factor 3.0 <italic>Recommended</italic></ext-link></p><p>Evaluated by Effie Petersdorf 29 Jul 2009</p></note></ref><ref id="bib-014"><label>14</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Lasho</surname><given-names>TL</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Patnaik</surname><given-names>MM</given-names></name><name><surname>Hanson</surname><given-names>CA</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><article-title>Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>1343</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19295549</pub-id><pub-id pub-id-type="doi">10.1038/leu.2009.59</pub-id></element-citation></ref><ref id="bib-015"><label>15</label><element-citation publication-type="journal"><person-group><name><surname>Landgren</surname><given-names>O</given-names></name><name><surname>Goldin</surname><given-names>LR</given-names></name><name><surname>Kristinsson</surname><given-names>SY</given-names></name><name><surname>Helgadottir</surname><given-names>EA</given-names></name><name><surname>Samuelsson</surname><given-names>J</given-names></name><name><surname>Bjorkholm</surname><given-names>M</given-names></name></person-group><article-title>Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24577 first-degree relatives of 11039 patients with myeloproliferative neoplasms in Sweden</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>2199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">18451307</pub-id><pub-id pub-id-type="doi">10.1182/blood-2008-03-143602</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1115124">f1000 Factor 3.0 <italic>Recommended</italic></ext-link></p><p>Evaluated by Jason Gotlib 19 Jun 2008</p></note></ref><ref id="bib-016"><label>16</label><element-citation publication-type="journal"><person-group><name><surname>Jones</surname><given-names>AV</given-names></name><name><surname>Chase</surname><given-names>A</given-names></name><name><surname>Silver</surname><given-names>RT</given-names></name><name><surname>Oscier</surname><given-names>D</given-names></name><name><surname>Zoi</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Cario</surname><given-names>H</given-names></name><name><surname>Pahl</surname><given-names>HL</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Reiter</surname><given-names>A</given-names></name><name><surname>Grand</surname><given-names>F</given-names></name><name><surname>Cross</surname><given-names>NC</given-names></name></person-group><article-title>JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>446</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19287382</pub-id><pub-id pub-id-type="doi">10.1038/ng.334</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1158658">f1000 Factor 6.4 <italic>Must Read</italic></ext-link></p><p>Evaluated by Monica Bessler 07 Apr 2009, Jason Gotlib 26 Jun 2009</p></note></ref><ref id="bib-017"><label>17</label><element-citation publication-type="journal"><person-group><name><surname>Olcaydu</surname><given-names>D</given-names></name><name><surname>Harutyunyan</surname><given-names>A</given-names></name><name><surname>Jager</surname><given-names>R</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Gisslinger</surname><given-names>B</given-names></name><name><surname>Pabinger</surname><given-names>I</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Kralovics</surname><given-names>R</given-names></name></person-group><article-title>A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>450</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">19287385</pub-id><pub-id pub-id-type="doi">10.1038/ng.341</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1158544">f1000 Factor 6.0 <italic>Must Read</italic></ext-link></p><p>Evaluated by Francesco Passamonti 31 Mar 2009</p></note></ref><ref id="bib-018"><label>18</label><element-citation publication-type="journal"><person-group><name><surname>Olcaydu</surname><given-names>D</given-names></name><name><surname>Skoda</surname><given-names>RC</given-names></name><name><surname>Looser</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Pietra</surname><given-names>D</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Lippert</surname><given-names>E</given-names></name><name><surname>Carillo</surname><given-names>S</given-names></name><name><surname>Girodon</surname><given-names>F</given-names></name><name><surname>Vannucchi</surname><given-names>A</given-names></name><name><surname>Reading</surname><given-names>NS</given-names></name><name><surname>Prchal</surname><given-names>JT</given-names></name><name><surname>Ay</surname><given-names>C</given-names></name><name><surname>Pabinger</surname><given-names>I</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Kralovics</surname><given-names>R</given-names></name></person-group><article-title>The &#x02018;GGCC&#x02019; haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>1924</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19440215</pub-id><pub-id pub-id-type="doi">10.1038/leu.2009.110</pub-id></element-citation></ref><ref id="bib-019"><label>19</label><element-citation publication-type="journal"><person-group><name><surname>Kilpivaara</surname><given-names>O</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Schram</surname><given-names>AM</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Mullally</surname><given-names>A</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Bass</surname><given-names>A</given-names></name><name><surname>Marubayashi</surname><given-names>S</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Klein</surname><given-names>RJ</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><article-title>A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>455</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19287384</pub-id><pub-id pub-id-type="doi">10.1038/ng.342</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1163272">f1000 Factor 6.0 <italic>Must Read</italic></ext-link></p><p>Evaluated by Sissy Jhiang 11 Aug 2009</p></note></ref><ref id="bib-020"><label>20</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Kvasnicka</surname><given-names>HM</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name><name><surname>Hanson</surname><given-names>CA</given-names></name><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Birgegard</surname><given-names>G</given-names></name><name><surname>Mesa</surname><given-names>R</given-names></name><name><surname>Reilly</surname><given-names>JT</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Finazzi</surname><given-names>G</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Vardiman</surname><given-names>JW</given-names></name></person-group><article-title>Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>1092</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17488875</pub-id><pub-id pub-id-type="doi">10.1182/blood-2007-04-083501</pub-id></element-citation><note><p><bold>Changes Clinical Practice</bold></p><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1087119">f1000 Factor 6.0 <italic>Must Read</italic></ext-link></p><p>Evaluated by Francesco Onida 28 Jun 2007</p></note></ref><ref id="bib-021"><label>21</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Swerdlow</surname><given-names>SH</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Pileri</surname><given-names>SA</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Vardiman</surname><given-names>JW</given-names></name></person-group><source>WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues</source><publisher-loc>Lyon, France</publisher-loc><publisher-name>International Agency for Research on Cancer</publisher-name><year>2008</year></element-citation></ref><ref id="bib-022"><label>22</label><element-citation publication-type="journal"><person-group><name><surname>Dentali</surname><given-names>F</given-names></name><name><surname>Squizzato</surname><given-names>A</given-names></name><name><surname>Brivio</surname><given-names>L</given-names></name><name><surname>Appio</surname><given-names>L</given-names></name><name><surname>Campiotti</surname><given-names>L</given-names></name><name><surname>Crowther</surname><given-names>M</given-names></name><name><surname>Grandi</surname><given-names>AM</given-names></name><name><surname>Ageno</surname><given-names>W</given-names></name></person-group><article-title>JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>5617</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19273837</pub-id><pub-id pub-id-type="doi">10.1182/blood-2008-12-196014</pub-id></element-citation></ref><ref id="bib-023"><label>23</label><element-citation publication-type="journal"><person-group><name><surname>Kiladjian</surname><given-names>JJ</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Leebeek</surname><given-names>FW</given-names></name><name><surname>Marzac</surname><given-names>C</given-names></name><name><surname>Cassinat</surname><given-names>B</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Cazals-Hatem</surname><given-names>D</given-names></name><name><surname>Plessier</surname><given-names>A</given-names></name><name><surname>Garcia-Pagan</surname><given-names>JC</given-names></name><name><surname>Murad</surname><given-names>SD</given-names></name><name><surname>Raffa</surname><given-names>S</given-names></name><name><surname>Janssen</surname><given-names>HL</given-names></name><name><surname>Gardin</surname><given-names>C</given-names></name><name><surname>Cereja</surname><given-names>S</given-names></name><name><surname>Tonetti</surname><given-names>C</given-names></name><name><surname>Giraudier</surname><given-names>S</given-names></name><name><surname>Condat</surname><given-names>B</given-names></name><name><surname>Casadevall</surname><given-names>N</given-names></name><name><surname>Fenaux</surname><given-names>P</given-names></name><name><surname>Valla</surname><given-names>DC</given-names></name></person-group><article-title>The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>4922</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18250227</pub-id><pub-id pub-id-type="doi">10.1182/blood-2007-11-125328</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1116380">f1000 Factor 3.0 <italic>Recommended</italic></ext-link></p><p>Evaluated by Jason Gotlib 08 Jul 2008</p></note></ref><ref id="bib-024"><label>24</label><element-citation publication-type="journal"><person-group><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Dupriez</surname><given-names>B</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Gotlib</surname><given-names>J</given-names></name><name><surname>Reilly</surname><given-names>JT</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Hanson</surname><given-names>CA</given-names></name><name><surname>Solberg</surname><given-names>LA</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>437</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17728787</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404914</pub-id></element-citation></ref><ref id="bib-025"><label>25</label><element-citation publication-type="journal"><person-group><name><surname>Ziakas</surname><given-names>PD</given-names></name></person-group><article-title>Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain</article-title><source>Haematologica</source><year>2008</year><volume>93</volume><fpage>1412</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">18641024</pub-id><pub-id pub-id-type="doi">10.3324/haematol.12970</pub-id></element-citation></ref><ref id="bib-026"><label>26</label><element-citation publication-type="journal"><person-group><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Antonioli</surname><given-names>E</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Marchioli</surname><given-names>R</given-names></name><name><surname>Marfisi</surname><given-names>RM</given-names></name><name><surname>Finazzi</surname><given-names>G</given-names></name><name><surname>Guerini</surname><given-names>V</given-names></name><name><surname>Fabris</surname><given-names>F</given-names></name><name><surname>Randi</surname><given-names>ML</given-names></name><name><surname>De Stefano</surname><given-names>V</given-names></name><name><surname>Caberlon</surname><given-names>S</given-names></name><name><surname>Tafuri</surname><given-names>A</given-names></name><name><surname>Ruggeri</surname><given-names>M</given-names></name><name><surname>Specchia</surname><given-names>G</given-names></name><name><surname>Liso</surname><given-names>V</given-names></name><name><surname>Rossi</surname><given-names>E</given-names></name><name><surname>Pogliani</surname><given-names>E</given-names></name><name><surname>Gugliotta</surname><given-names>L</given-names></name><name><surname>Bosi</surname><given-names>A</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name></person-group><article-title>Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>840</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17379742</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-12-064287</pub-id></element-citation></ref><ref id="bib-027"><label>27</label><element-citation publication-type="journal"><person-group><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Antonioli</surname><given-names>E</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Longo</surname><given-names>G</given-names></name><name><surname>Pancrazzi</surname><given-names>A</given-names></name><name><surname>Ponziani</surname><given-names>V</given-names></name><name><surname>Bogani</surname><given-names>C</given-names></name><name><surname>Ferrini</surname><given-names>PR</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Guerini</surname><given-names>V</given-names></name><name><surname>Bosi</surname><given-names>A</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name></person-group><article-title>Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>1952</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17625606</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404854</pub-id></element-citation></ref><ref id="bib-028"><label>28</label><element-citation publication-type="journal"><person-group><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Rumi</surname><given-names>E</given-names></name><name><surname>Pietra</surname><given-names>D</given-names></name><name><surname>Della Porta</surname><given-names>MG</given-names></name><name><surname>Boveri</surname><given-names>E</given-names></name><name><surname>Pascutto</surname><given-names>C</given-names></name><name><surname>Vanelli</surname><given-names>L</given-names></name><name><surname>Arcaini</surname><given-names>L</given-names></name><name><surname>Burcheri</surname><given-names>S</given-names></name><name><surname>Malcovati</surname><given-names>L</given-names></name><name><surname>Lazzarino</surname><given-names>M</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name></person-group><article-title>Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>3676</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">16373657</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-09-3826</pub-id></element-citation></ref><ref id="bib-029"><label>29</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Lasho</surname><given-names>TL</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Finke</surname><given-names>C</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Hanson</surname><given-names>CA</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name></person-group><article-title>Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>756</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18216871</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2405097</pub-id></element-citation></ref><ref id="bib-030"><label>30</label><element-citation publication-type="journal"><person-group><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Specchia</surname><given-names>G</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Lo Coco</surname><given-names>F</given-names></name><name><surname>Antonioli</surname><given-names>E</given-names></name><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Pancrazzi</surname><given-names>A</given-names></name><name><surname>Ponziani</surname><given-names>V</given-names></name><name><surname>Delaini</surname><given-names>F</given-names></name><name><surname>Longo</surname><given-names>G</given-names></name><name><surname>Ammatuna</surname><given-names>E</given-names></name><name><surname>Liso</surname><given-names>V</given-names></name><name><surname>Bosi</surname><given-names>A</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name></person-group><article-title>Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>1477</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">19549988</pub-id><pub-id pub-id-type="doi">10.1182/blood-2009-04-216044</pub-id></element-citation></ref><ref id="bib-031"><label>31</label><element-citation publication-type="journal"><person-group><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Antonioli</surname><given-names>E</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>1299</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">18496562</pub-id><pub-id pub-id-type="doi">10.1038/leu.2008.113</pub-id></element-citation></ref><ref id="bib-032"><label>32</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Lasho</surname><given-names>TL</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Gangat</surname><given-names>N</given-names></name><name><surname>Finke</surname><given-names>CM</given-names></name><name><surname>Schwager</surname><given-names>S</given-names></name><name><surname>Mullally</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Hanson</surname><given-names>CA</given-names></name><name><surname>Mesa</surname><given-names>R</given-names></name><name><surname>Bernard</surname><given-names>O</given-names></name><name><surname>Delhommeau</surname><given-names>F</given-names></name><name><surname>Vainchenker</surname><given-names>W</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><article-title>TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>905</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">19262601</pub-id><pub-id pub-id-type="doi">10.1038/leu.2009.47</pub-id></element-citation></ref><ref id="bib-033"><label>33</label><element-citation publication-type="journal"><person-group><name><surname>Barbui</surname><given-names>T</given-names></name><name><surname>Carobbio</surname><given-names>A</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Finazzi</surname><given-names>G</given-names></name></person-group><article-title>Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>759</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19372254</pub-id></element-citation></ref><ref id="bib-034"><label>34</label><element-citation publication-type="journal"><person-group><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Dupriez</surname><given-names>B</given-names></name><name><surname>Pereira</surname><given-names>A</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Reilly</surname><given-names>JT</given-names></name><name><surname>Morra</surname><given-names>E</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Demory</surname><given-names>JL</given-names></name><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Rumi</surname><given-names>E</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>2895</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">18988864</pub-id><pub-id pub-id-type="doi">10.1182/blood-2008-07-170449</pub-id></element-citation></ref><ref id="bib-035"><label>35</label><element-citation publication-type="journal"><person-group><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Morra</surname><given-names>E</given-names></name><name><surname>Rumi</surname><given-names>E</given-names></name><name><surname>Pereira</surname><given-names>A</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Pungolino</surname><given-names>E</given-names></name><name><surname>Caramella</surname><given-names>M</given-names></name><name><surname>Maffioli</surname><given-names>M</given-names></name><name><surname>Pascutto</surname><given-names>C</given-names></name><name><surname>Lazzarino</surname><given-names>M</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)</article-title><source>Blood</source><year>2009</year><comment>[Epub ahead of print]</comment><pub-id pub-id-type="pmid">20008785</pub-id></element-citation></ref><ref id="bib-036"><label>36</label><element-citation publication-type="journal"><person-group><name><surname>Pardanani</surname><given-names>A</given-names></name></person-group><article-title>JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">17882282</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404948</pub-id></element-citation></ref><ref id="bib-037"><label>37</label><element-citation publication-type="journal"><person-group><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Kharas</surname><given-names>MG</given-names></name><name><surname>Okabe</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>SA</given-names></name><name><surname>Leeman</surname><given-names>DS</given-names></name><name><surname>Cullen</surname><given-names>DE</given-names></name><name><surname>Gozo</surname><given-names>M</given-names></name><name><surname>McDowell</surname><given-names>EP</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Doukas</surname><given-names>J</given-names></name><name><surname>Mak</surname><given-names>CC</given-names></name><name><surname>Noronha</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Ko</surname><given-names>YD</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Soll</surname><given-names>RM</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Hood</surname><given-names>JD</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name></person-group><article-title>Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><fpage>311</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">18394554</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2008.02.009</pub-id></element-citation></ref><ref id="bib-038"><label>38</label><element-citation publication-type="journal"><person-group><name><surname>Verstovsek</surname><given-names>S</given-names></name></person-group><article-title>Therapeutic potential of JAK2 inhibitors</article-title><source>Hematology Am Soc Hematol Educ Program</source><year>2009</year><fpage>636</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20008249</pub-id><pub-id pub-id-type="doi">10.1182/asheducation-2009.1.636</pub-id></element-citation></ref><ref id="bib-039"><label>39</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Lasho</surname><given-names>TL</given-names></name><name><surname>Hogan</surname><given-names>WJ</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Allred</surname><given-names>JB</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Byrne</surname><given-names>C</given-names></name><name><surname>Zeldis</surname><given-names>JB</given-names></name><name><surname>Ketterling</surname><given-names>RP</given-names></name><name><surname>McClure</surname><given-names>RF</given-names></name><name><surname>Giles</surname><given-names>F</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name></person-group><article-title>Lenalidomide therapy in myelofibrosis with myeloid metaplasia</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>1158</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">16609064</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-02-004572</pub-id></element-citation></ref><ref id="bib-040"><label>40</label><element-citation publication-type="journal"><person-group><name><surname>Quintas-Cardama</surname><given-names>A</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Manshouri</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Ferrajoli</surname><given-names>A</given-names></name><name><surname>Bueso-Ramos</surname><given-names>C</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name></person-group><article-title>Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>4760</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19720904</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2009.22.6548</pub-id></element-citation></ref><ref id="bib-041"><label>41</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Lasho</surname><given-names>TL</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Ketterling</surname><given-names>RP</given-names></name><name><surname>Hanson</surname><given-names>CA</given-names></name></person-group><article-title>Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>1827</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17460705</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404711</pub-id></element-citation></ref><ref id="bib-042"><label>42</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Roboz</surname><given-names>GJ</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Paquette</surname><given-names>RL</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Rivera</surname><given-names>CE</given-names></name><name><surname>Deeg</surname><given-names>HJ</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Kvasnicka</surname><given-names>HM</given-names></name><name><surname>Vardiman</surname><given-names>JW</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bekele</surname><given-names>BN</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Gale</surname><given-names>RP</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name></person-group><article-title>Pomalidomide is active in the treatment of anemia associated with myelofibrosis</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>4563</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19652059</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2008.21.7356</pub-id></element-citation></ref><ref id="bib-043"><label>43</label><element-citation publication-type="journal"><person-group><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Camoriano</surname><given-names>JK</given-names></name><name><surname>Geyer</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>Rivera</surname><given-names>CE</given-names></name><name><surname>Erlichman</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Lasho</surname><given-names>T</given-names></name><name><surname>Finke</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>1964</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17581608</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404816</pub-id></element-citation></ref><ref id="bib-044"><label>44</label><element-citation publication-type="journal"><person-group><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Bogani</surname><given-names>C</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name></person-group><article-title>Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives</article-title><source>J Cell Mol Med</source><year>2009</year><volume>13</volume><fpage>1437</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">19522842</pub-id><pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00827.x</pub-id></element-citation></ref><ref id="bib-045"><label>45</label><element-citation publication-type="journal"><person-group><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Gottgens</surname><given-names>B</given-names></name><name><surname>Foster</surname><given-names>SD</given-names></name><name><surname>Bartke</surname><given-names>T</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><article-title>JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin</article-title><source>Nature</source><year>2009</year><volume>461</volume><fpage>819</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19783980</pub-id><pub-id pub-id-type="doi">10.1038/nature08448</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000biology.com/article/id/1166393">f1000 Factor 6.5 <italic>Must Read</italic></ext-link></p><p>Evaluated by Andrew D Sharrocks 21 Oct 2009, Brent Cochran 27 Oct 2009, Warren Leonard 04 Jan 2010</p></note></ref><ref id="bib-046"><label>46</label><element-citation publication-type="journal"><person-group><name><surname>Tahiliani</surname><given-names>M</given-names></name><name><surname>Koh</surname><given-names>KP</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Pastor</surname><given-names>WA</given-names></name><name><surname>Bandukwala</surname><given-names>H</given-names></name><name><surname>Brudno</surname><given-names>Y</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Iyer</surname><given-names>LM</given-names></name><name><surname>Liu</surname><given-names>DR</given-names></name><name><surname>Aravind</surname><given-names>L</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><article-title>Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>930</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19372391</pub-id><pub-id pub-id-type="doi">10.1126/science.1170116</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000biology.com/article/id/1159124">f1000 Factor 9.9 <italic>Exceptional</italic></ext-link></p><p>Evaluated by Stephan Beck 21 Apr 2009, Steven Henikoff 22 Apr 2009, Yi Eve Sun 23 Sep 2009, Christopher Schofield 30 Oct 2009</p></note></ref><ref id="bib-047"><label>47</label><element-citation publication-type="journal"><person-group><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Rivera</surname><given-names>C</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Hussein</surname><given-names>K</given-names></name><name><surname>Lasho</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>5-Azacitidine has limited therapeutic activity in myelofibrosis</article-title><source>Leukemia</source><year>2008</year><volume>23</volume><fpage>180</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">18509350</pub-id><pub-id pub-id-type="doi">10.1038/leu.2008.136</pub-id></element-citation></ref><ref id="bib-048"><label>48</label><element-citation publication-type="journal"><person-group><name><surname>Quintas-Cardama</surname><given-names>A</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Manshouri</surname><given-names>T</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name></person-group><article-title>A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>965</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">18385750</pub-id><pub-id pub-id-type="doi">10.1038/leu.2008.91</pub-id></element-citation><note><p><ext-link ext-link-type="uri" xlink:href="www.f1000medicine.com/article/id/1115745">f1000 Factor 3.0 <italic>Recommended</italic></ext-link></p><p>Evaluated by Nikolaus Kroeger 30 Jul 2008</p></note></ref><ref id="bib-049"><label>49</label><element-citation publication-type="journal"><person-group><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Dellacasa</surname><given-names>CM</given-names></name><name><surname>Salmoiraghi</surname><given-names>S</given-names></name><name><surname>Spinelli</surname><given-names>O</given-names></name><name><surname>Ferrari</surname><given-names>ML</given-names></name><name><surname>Gattoni</surname><given-names>E</given-names></name><name><surname>Guglielmelli</surname><given-names>P</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name></person-group><article-title>A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms</article-title><source>Blood (ASH Annual Meeting Abstracts)</source><year>2008</year><volume>112</volume><fpage>100A</fpage></element-citation></ref><ref id="bib-050"><label>50</label><element-citation publication-type="journal"><person-group><name><surname>Kiladjian</surname><given-names>JJ</given-names></name><name><surname>Cassinat</surname><given-names>B</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Turlure</surname><given-names>P</given-names></name><name><surname>Cambier</surname><given-names>N</given-names></name><name><surname>Roussel</surname><given-names>M</given-names></name><name><surname>Bellucci</surname><given-names>S</given-names></name><name><surname>Grandchamp</surname><given-names>B</given-names></name><name><surname>Chomienne</surname><given-names>C</given-names></name><name><surname>Fenaux</surname><given-names>P</given-names></name></person-group><article-title>Pegylated interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>3065</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">18650451</pub-id><pub-id pub-id-type="doi">10.1182/blood-2008-03-143537</pub-id></element-citation></ref><ref id="bib-051"><label>51</label><element-citation publication-type="journal"><person-group><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Deeg</surname><given-names>HJ</given-names></name><name><surname>Reilly</surname><given-names>JT</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Dupriez</surname><given-names>B</given-names></name><name><surname>Silver</surname><given-names>RT</given-names></name><name><surname>Odenike</surname><given-names>O</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Solberg</surname><given-names>LA</given-names><suffix>Jr</suffix></name><name><surname>Camoriano</surname><given-names>JK</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Noel</surname><given-names>P</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Vardiman</surname><given-names>JW</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Cross</surname><given-names>NC</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name></person-group><article-title>International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>1497</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">16675707</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-03-009746</pub-id></element-citation></ref><ref id="bib-052"><label>52</label><element-citation publication-type="journal"><person-group><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Bordessoule</surname><given-names>D</given-names></name><name><surname>Briere</surname><given-names>J</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Demory</surname><given-names>JL</given-names></name><name><surname>Dupriez</surname><given-names>B</given-names></name><name><surname>Gisslinger</surname><given-names>H</given-names></name><name><surname>Griesshammer</surname><given-names>M</given-names></name><name><surname>Hasselbalch</surname><given-names>H</given-names></name><name><surname>Kusec</surname><given-names>R</given-names></name><name><surname>Le Bousse-Kerdiles</surname><given-names>MC</given-names></name><name><surname>Liberato</surname><given-names>NL</given-names></name><name><surname>Marchetti</surname><given-names>M</given-names></name><name><surname>Reilly</surname><given-names>JT</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name></person-group><article-title>Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>2849</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15994287</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-04-1520</pub-id></element-citation></ref><ref id="bib-053"><label>53</label><element-citation publication-type="journal"><person-group><name><surname>Barosi</surname><given-names>G</given-names></name><name><surname>Birgegard</surname><given-names>G</given-names></name><name><surname>Finazzi</surname><given-names>G</given-names></name><name><surname>Griesshammer</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>C</given-names></name><name><surname>Hasselbalch</surname><given-names>HC</given-names></name><name><surname>Kiladjian</surname><given-names>JJ</given-names></name><name><surname>Lengfelder</surname><given-names>E</given-names></name><name><surname>McMullin</surname><given-names>MF</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Reilly</surname><given-names>JT</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name></person-group><article-title>Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>4829</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">19278953</pub-id><pub-id pub-id-type="doi">10.1182/blood-2008-09-176818</pub-id></element-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list id="dl1"><def-item><term>AML</term><def><p>acute myeloid leukemia</p></def></def-item><def-item><term>ET</term><def><p>essential thrombocythemia</p></def></def-item><def-item><term>IFN</term><def><p>interferon</p></def></def-item><def-item><term>IWG-MRT</term><def><p>International Working Group for Myelofibrosis Research and Treatment</p></def></def-item><def-item><term>JAK</term><def><p>Janus kinase</p></def></def-item><def-item><term>JAK-STAT</term><def><p>JAK-signal transducer and activator of transcription</p></def></def-item><def-item><term>MPL</term><def><p>myeloproliferative leukemia virus oncogene</p></def></def-item><def-item><term>MPN</term><def><p>myeloproliferative neoplasm</p></def></def-item><def-item><term>PMF</term><def><p>primary myelofibrosis</p></def></def-item><def-item><term>PPV/PET-MF</term><def><p>post-polycythemia vera/post-essential thrombocythemia myelofibrosis</p></def></def-item><def-item><term>PV</term><def><p>polycythemia vera</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item></def-list></glossary></back></article>